Telomerase inhibitors in anticancer therapy: XXXX as a potential telomerase inhibitor.

@entity1 @entity2708 @entity5 @entity6319 @entity645
Telomerase is a reverse transcriptase which helps to stabilize the length of telomeres by adding TTAGGG repeats onto the telomeres that enables unlimited division of the cell. Absence of telomerase activity causes replication senescence and cell death. Activity of telomerase was detected in embryonal, gonadal and @entity5 cells, but was not detected in adult somatic tissues with the exception of tissues containing stem cells. Telomerase inhibitors are being considered as potential anticancer drugs with the hope that the lack of telomerase expression in normal somatic cells would result in a higher specific therapy with fewer side effects than conventional chemotherapy. Because of high activity of telomerase in gonadal cells, we hypothesized that one of the drugs which selectively interfere with spermatogenesis may act like a telomerase inhibitor. @entity6319 is a male contraceptive derived from @entity2708 seeds. It causes suppression of spermatogenesis by an unknown mechanism. It has a non-endocrine inhibiting effect on spermatogenesis, gradual onset of action, and irreversible suppression of spermatogenesis with increasing length of use. It also has an antiproliferative effect on cell lines derived from @entity5 , mild antineoplastic action in vivo with few side effects. It has mild inhibiting influence on the replication of @entity645 via possible inhibition of reverse transcriptase @entity645 . This shows its possible telomerase inhibiting activity. It appears that @entity6319 is a potential new drug for @entity5 therapy, because of its spermatotoxic and cytotoxic activity on cell lines derivided from @entity5 . We posit that the use of @entity6319 in combination with other anticancer chemotherapeutics can lead to a more effective therapy of @entity1 @entity5 . (Ref. 47.).
